Dossier: A “Second Opinion” App for Longevity Lab Results

What you’re reading: a real Opportunity Dossier from our AI research pipeline — Ada spotted the signals, Bea shaped the candidates, Cora dug deep, Edie tried to kill it and owns the score, and Della wrote it up. New to our scoring? Start with How Our Star Score Works. Research date: July 2026 — facts move; check dates before betting money.

In one line: An app that reads all your scattered health numbers — your “biological age” tests, your blood work, your smartwatch data — and tells you honestly which anti-aging tricks are actually backed by real proof and which are just hype.

Super Fluidity deep report · early look · 2026-07-10 · from our longevity watch-list

The short version

First, the good news for this idea. The person who pitched it got the core problem right. People who care about living longer really are drowning in confusing test results, and they’ve lost trust in the famous “longevity” influencers. On top of that, the “biological age” tests are genuinely shaky — take the same test twice and the answer can jump by as much as 9 years. So the dream of one honest, trustworthy app that reads all your numbers and tells you the plain truth? That’s a real, appealing dream.

Now the bad news, and it’s the part that sinks the score. The pitch leaned on one big claim: that nobody has built this yet, so the door is wide open. That claim is wrong, and it’s getting more wrong by the month.

A company called Superpower ($199 a year) already sells almost exactly this product: upload your old lab results, connect your Oura ring or Whoop band or Apple Health, and get an AI reading of what it all means. And a bigger company, Function Health ($365 a year, over 200,000 paying members, valued at $2.5 billion, and just handed $298 million by investors in November 2025), launched its own AI “reading” engine — and they have a huge advantage, because they sell you the blood tests in the first place. A whole crowd of other companies (Neura Health, HealthForge, Heads Up Health, HolistiCare, Longevitix, LongevityMate) are already crowding in from every angle.

So where’s the one spot nobody has taken? It’s not collecting all your data — the big companies already have way more of your data than a newcomer ever could, and they own the relationship because they sell the tests. The one truly hard-to-copy angle is being neutral: grading the evidence like a referee and selling nothing else — no tests, no supplements, no protocols. Think of it like “Examine.com, but for your own personal health plan” — a place that will flat-out tell you “this popular pill? The big trial showed it doesn’t work,” with the proof attached. But here’s the catch: that’s really a writing-and-research business with a bit of software on top. People won’t pay a fortune for it, and it won’t grow into a giant company.

The idea is easy and cheap to build — it’s just software, no lab, no big money, a working first version in 2 to 4 months. The real question isn’t “can you build it?” It’s “will anyone pay for a plain honest reading when the test companies give that reading away free to sell you the test?” That’s the whole ballgame. This is a perfect case for testing by hand, cheaply, before building anything.

Our reviewer’s verdict: Two stars. The pain is real and confirmed, the wind is at your back, and there’s one thing nobody can copy — true neutrality, selling only the honest read, which no big company can match without hurting its own sales. But the pitch’s main claim (“nobody’s built this yet”) is simply false: Superpower already sells it at $199, Function ($2.5 billion, $298 million, its own AI reading engine) is bundling it in while owning the test relationship, and the “reading” is being turned into a free add-on to reel customers in. Still, nothing here is a total zero — it’s buildable, cheap, and legal if you word things carefully. That’s exactly why the verdict is: don’t pour your time into it, but DO run the cheap test first — while expecting that test to come back “no.”

The scorecard

What we scored	Score	Why
How fast you’d learn the truth	4/5	The one big unknown — will people pay? — is unusually cheap to check. A simple web page or 10 to 20 hand-made reports with a real “will you pre-pay?” ask settles it in weeks for under $5,000. Nothing standing in the way.
How fast you’d have a working version	3/5	2 to 4 months on your own (reading the PDFs, pulling in Apple Health data, an AI kept on a leash by rules you write). The slow part isn’t the coding — it’s writing the honest-grading rulebook and getting a lawyer to check your health wording.
How fast you’d get a first paying customer	3/5	The health-obsessed buyer is reachable in 1 to 3 months of outreach, but a “trust me, I’m neutral” brand has to earn trust before it earns dollars — and $15-a-month copycat apps are pushing the price toward nothing.
How much money you’d need to start	4/5	You can fund it yourself — just AI costs and web hosting, no lab, no gadgets, no stuff to stock. The one real bill is a proper lawyer’s review of your health claims (a few thousand dollars), which keeps it off a perfect score.
How hard it is to run day to day	3/5	Medium, with a legal cloud overhead: a new FDA rule (January 2026) can treat software that “recommends” things to patients as a medical device. Add finicky PDF-reading, consent forms, and endless updating as new studies come out.
How crowded it already is	2/5	This is the killer. Superpower sells the exact product today; Function ($2.5 billion, its own AI reader) is building it as a free bonus with the test; Examine already owns “graded evidence.” One empty seat remains — true neutrality — which keeps it off a zero.
Is the timing good?	4/5	Strong wind at your back: the longevity market is about $27.6 billion (2025) heading to about $67 billion by 2035, growing roughly 9% a year, with about 120 million interested customers. The trust crisis creates real demand for an honest referee — but this specific software corner is already running late.
Does AI help?	3/5	A double-edged sword. AI does the hard reading work, so one person can build it — but AI is also the exact reason this whole layer is becoming free, since every well-funded competitor is bolting one on. Your real asset is the hand-written rulebook, not the AI.
How hard is it to copy?	2/5	The “we’ll own the most data” edge actually favors the big guys (Function has 200,000+ members and 50 million+ tests); you’d start at zero. The one lasting edge — neutrality, which rivals can’t copy without hurting their own sales — is real but thin, and grows slowly.

Overall: ★★☆☆☆ (2/5)

Two stars: a weak case on its own, saved only by how cheaply you can test it. The pain is real and confirmed (confusing results, lost trust, that 9-year wobble in the tests), the timing wind is strong, and there’s one un-copyable angle — pure neutrality, selling only the honest read, which no big company can match without hurting its own sales. But the pitch’s load-bearing claim (“nobody’s built this yet”) is false: Superpower sells it at $199 today, Function ($2.5 billion, $298 million, its own AI reader) is bundling it while owning the test relationship, and the reading is turning free as a way to grab customers. The only defensible piece is a modest-earning writing-and-research product that never stops needing updates — in a field where Examine already owns “graded evidence.” Honestly, this looks like a feature inside a bigger company, not a company of its own. Nothing is a fatal zero (it’s buildable, cheap, legal with care) — which is exactly why the verdict is “don’t spend your time on it, but DO run the cheap test first,” expecting a “no.” **One important note: longevity’s “the door is still open, it’s early” protection applies to the underlying science, NOT to this already-crowding software corner — so it doesn’t rescue the score.**

Who this is for (and who it isn’t)

Person A — The tech builder (about 10 hours a week, can write code, has no following, about $2,000 to spend) → adjusted score: 2/5 No help on the thing that matters. Being able to build it doesn’t count for much here, because the real hurdle is demand and a trusted neutral brand — and they have neither. The winning edge is writing and reaching people, not code. Their $2,000 also won’t cover the health-claim lawyer this needs. This is the person most likely to build a gorgeous copycat feature that nobody pays for. Stays at 2, leaning down.

Person B — The non-tech operator (about 20 hours a week, about $20,000, great at running things, can’t code) → adjusted score: 2/5 Docked points on building (this is genuinely software-heavy and they can’t ship it), but the real treasure — the hand-written evidence rulebook — is writing work they could own, and $20,000 comfortably covers the legal wording plus a real hand-run paid test. Better set up than Person A to actually run the make-or-break test. Still slams into the same demand-and-competition wall. Net: flat at 2.

Person C — The person who already has an audience (a real longevity email list or following, not much time, sells well) → adjusted score: 3/5 The only one who clears the bar. Their existing trusted crowd solves the two hardest parts — getting in front of people and being believed — and a neutral, “here’s what actually doesn’t work” voice is exactly what a good writer-with-an-audience does best (Examine is a writing brand). Getting first customers and being hard to copy both go up; an existing longevity following could carry a modest subscription that a stranger never could. This is where the neutrality angle becomes a real, if small, business. Bumped up to 3.

Why now

The big wave is genuinely early and huge: the longevity market is roughly $27.6 billion (2025), growing about 9% a year toward about $67 billion by 2035, with an estimated 120 million interested customers worldwide. A real trust crisis is adding fuel — people are side-eyeing famous longevity figures like Peter Attia, and a big rapamycin study called PEARL quietly showed its main goal didn’t pan out. That’s creating genuine hunger for a neutral, “let’s be honest about what doesn’t work” referee — on top of the fact that the biological-age tests themselves are shaky (up to 9 years of wobble when you run the same test twice).

But that “the window is still open, it’s early” logic applies to the science, not to this software corner. This particular layer is running late and is filling up fast: Superpower sells the pitched product today at $199 a year, and Function Health — freshly loaded with cash at a $2.5 billion valuation from a $298 million round (November 2025) — already launched its own AI reading engine while owning the test-buying relationship. The reading is drifting toward a free bonus rather than a product you pay for. The one genuinely open seat is narrow: pure neutrality — selling only the honest read — which no big company can take without hurting its own test and supplement sales. That seat is real, but it’s a crack in the door, not an open field.

What the product actually is

People chasing longevity increasingly stack up multiple products — a TruDiagnostic “epigenetic age” test, a Function or Superpower blood panel, an Oura ring or a continuous glucose monitor — and end up with a pile of scattered dashboards and no single clear answer about what any of it means. They’ve lost trust (after Attia and after PEARL), they want to know which treatments (rapamycin, NMN/NAD, senolytics) are actually backed by real studies versus hype, and they have no way to make sense of two biological-age tests that disagree.

Doctors at longevity clinics face the same headache, and they admit it: getting the data is easy, but pulling labs, genetics, wearables, and medical records into one clear, defensible plan is not.

The pitched product is a web app that swallows your existing lab PDFs and smartwatch exports, lines up your different biological-age readings (with honest warnings about how noisy they are), and lays an Examine-style graded-evidence read — with citations, and clear flags for things that didn’t work — over each treatment you’re taking or thinking about. Its whole pitch is that it’s neutral, because it sells nothing but the honest read.

Who wants this

People chasing longevity who already buy several products (a biological-age test plus a blood panel plus an Oura ring or glucose monitor) end up with scattered dashboards and no single clear read.
Deep distrust of longevity influencers after Attia and after PEARL: buyers want to know which treatments (rapamycin, NMN/NAD, senolytics) are actually backed by studies versus hype and paid promotion.
Biological-age results genuinely disagree and are noisy: different tests give different numbers, and people have no way to square “one test says X, the other says Y” (up to 9 years of wobble between repeat tests).
Longevity doctors openly admit a “reading crisis” — getting the data is solved, but turning labs plus genetics plus wearables plus medical records into one clear, defensible plan is not (this is the business-clinic pain that HolistiCare, Longevitix, and Heads Up chase).
Regular buyers can’t tell whether a personalized supplement or protocol suggestion is actually backed by evidence or is just an upsell tied to a company’s own product line.

Who you’d be up against

Name	Price	What to know
Function Health	$365/year (160+ tests, doctor review); dropped from $499	The 800-pound gorilla moving into reading your results. 200,000+ members, 50 million+ lab tests, roughly $100 million a year coming in, $2.5 billion valuation on a $298 million round (led by Redpoint, with a16z, November 2025). Launched its own AI “Medical Intelligence Lab” reader. Owns your data because it sells you the tests.
Superpower	$199/year (100+ health markers, HSA/FSA eligible); dropped from $499	The closest thing to the pitched product, and already live: upload old labs, connect Oura/Whoop/Apple Health, get an AI assistant “within strict clinical guardrails” giving “evidence-backed reasoning.” Raised about $30 million.
TruDiagnostic (TruAge)	$499 one-time; $249 per test on Subscribe & Save	A biological-age data source. Building its own reading tools (with Harvard and Yale). No public way for outside software to plug in; others get access only through partnerships or research deals.
Examine.com	about $19/month (Examine+)	Already owns the “graded evidence” name: A-to-F grades across 500+ treatments, with effect sizes and citations. But it grades supplements in general, not your personal lab results.
Neura Health / HealthForge	Consumer subscription (tiered)	Consumer apps already connecting 90+ other apps and devices — meaning the “gather all your data” piece is largely built already.
HolistiCare / Longevitix / Heads Up Health	Software sold to clinics	The business-side answer to the doctors’ “reading crisis” — already a contested space.
LongevityMate	$14.99/month or $134.91/year	A thin “AI longevity helper for blood work and wearables” — proof that the price floor is low and there’s real pressure on how much anyone will pay.

The gaps nobody has filled

Honest grading tied to your own results: no consumer app combines Examine-style A-to-F grades with your personal, cross-lab data and clearly flags what is not supported (rapamycin’s PEARL letdown, weak NAD/NMN evidence). The big companies’ AI is built to recommend things, not to tell you what doesn’t work.
True neutrality: Function, Superpower, and TruDiagnostic all sell the test or the protocol, so their reading has a built-in conflict of interest. An app that sells nothing but the honest read is a spot nobody credibly holds.
Explaining why two tests disagree: telling someone why their two biological-age tests give different numbers is genuinely unserved — and it’s exactly where the distrust lives.
Lining up to a neutral standard (XPRIZE Healthspan): worth noting, but this is a 2030, treatment-focused contest, not a consumer data standard — so the “get in early on the standard” angle is somewhat overstated.

What’s happening in this market

Big and growing wind at your back: the broad longevity market is put at about $27.6 billion (2025), growing roughly 9% a year to about $67 billion by 2035, about 120 million customers, with direct-to-consumer the biggest channel. But the specific “read my results” corner is filling up fast, and against a newcomer. Function’s $2.5 billion valuation, $298 million raise, and its own AI reader — plus Superpower’s price crash to $199 with upload, sync, and AI all built in — signal that deep-pocketed companies are turning “reading” into a free bonus that sells the test. That’s exactly the protected position a standalone reader can’t match. The one current pushing the other way, in the idea’s favor, is the trust crisis and the proven shakiness of the underlying tests, which creates real demand for a neutral honest referee. Bottom line: strong theme momentum, but the door on this specific “open reading layer” is closing, and the big companies own the pipe.

How you’d make money

A consumer subscription, about $99 to $149 a year, sold as the neutral “second opinion on the evidence” that sits on top of whatever labs you already buy — pointedly not selling labs, because neutrality is the brand. (That rules out earning commissions for referring people to labs or supplements, since that would poison the honest-broker image — treat that kind of income as brand-toxic.) The real defensible asset is the hand-written grading rulebook and editorial voice (Examine-like), so treat this as a writing business with a software delivery layer, not a “we own the most data” play.

A backup path if the consumer version stalls: sell the grading engine to longevity clinics (the Heads Up / HolistiCare space), where clinics will pay more and openly feel the “reading crisis.” Either way, keep the wording “here’s the information / here’s the evidence” so you stay on the safe side of FDA rules and don’t trip into practicing medicine and needing doctor oversight.

The marketing plan (make it before you build)

Let me be straight with you first, because it changes everything that follows. This idea got two stars. And the problem was never “you can’t find the customers.” The problem is that the thing you want to sell — a neutral, honest read — is being handed out free by the companies that sell the tests. No marketing fixes that. There’s no clever trick that turns a free-somewhere-else product into one people pay for. So read this section as: if you build it anyway, here’s the only route that has a shot — not as a plan that saves the score.

And here’s the sharpest thing I can tell you. Everywhere else in this report, the whole question was: will anyone actually pay? Marketing is that same question wearing a different hat. The one kind of person this works for — someone who already has a longevity audience that trusts them (“Person C” in the scorecard) — works because they already solved the hard part: people believe them. Everyone else has to earn that trust from scratch. And you can’t buy trust with ad money.

Before you build anything

Don’t wait for the app to be done. Your first marketing move is the same cheap test I keep coming back to: the pre-sell page.

Make the kill test your launch. The one-page offer (“a neutral, evidence-graded second opinion — we sell nothing but the honest read — $129/year, founding members”) does two jobs at once. If it flops, that’s a cheap “no.” If it works, the people who paid are your first thirty customers and your first thirty testimonials. One move, two payoffs.
Collect a waitlist, not just emails. A simple waitlist page is the cheapest little audience you can start building. For what it’s worth, waitlist pages turn about 11% of visitors into signups (Waitlister / GetWaitlist) — better than a regular product page. But a signup isn’t a sale. For consumer stuff, only about 5–15% of a waitlist ever pays (Waitlister). So gather signups, sure, but only count the people who pre-pay as a real yes.
Go where these folks already hang out. The people who’ll pay are already spending money on this — they’re in longevity newsletters, biohacking groups, and longevity-clinic waiting rooms. Show up like a person, not an ad. Answer “which of my two age tests should I trust?” honestly and for free, and let the honest voice do the work. It’s slow, one-person-at-a-time stuff. It’s also the only kind that builds the trust this whole thing runs on.
Start the partner talks early. Two kinds of partner matter here: (1) someone who owns a trusted audience (a longevity newsletter writer or podcaster whose readers already believe them), and (2) a longevity clinic that feels the “reading crisis” directly and might pay for the grading engine. Both take weeks to build. Start before you launch, not after.

The three ways you’d actually reach people

Only a few ways to reach people fit a product whose whole value is being believed. One quick term first: CPM just means what you pay to get your message in front of a thousand readers.

1. Borrowed trust — getting mentioned inside newsletters and podcasts people already trust. You can’t buy trust, but you can borrow it. When a longevity writer their readers believe says “I checked this out, it’s genuinely neutral,” that belief carries over in a way a cold ad never does. This fits because the product is trust, and a trusted voice is the only thing that carries it. Getting placed in a health-and-wellness newsletter runs about $40–$100 CPM (beehiiv, Newsletrix), and a host-read podcast mention runs roughly $25 CPM for a mid-roll spot (Influencer Marketing Hub). The catch — you’ll see it in the cost section — is that the math is tight. So the smart version is an earned mention or a revenue-share deal, not a paid banner.

2. Evidence writing that shows up on Google — the Examine.com move. Your buyer is already typing “is rapamycin worth it” or “does NMN actually work” into Google at the exact moment they’re doubting. Be there. Write genuinely neutral, graded reads — “here’s what the PEARL trial actually showed,” with the citations — and let Google find them. This fits for three reasons: it catches people right when they need it instead of interrupting them; the articles you write are the product’s grading rulebook (same work, done once, used twice); and it’s the one thing that snowballs — each customer’s search finds writing that pulls in the next. Examine.com got to over a million visits a month from Google, mostly on evidence writing and links from places like the New York Times and Forbes, plus repeat mentions on the Huberman Lab podcast — with zero paid outreach (Ahrefs case study). The honest warning: that took years, and Examine still got knocked down 90% by a single Google update in 2018. This is a slow-growing thing you own, not a launch-week trick.

3. Just reaching out, one by one, to the people already spending. The narrowest and most reliable way is also the least flashy: personally reach the 30–50 people already buying TruDiagnostic tests, Function panels, and Oura rings, and make them a founding-member offer. This is the kill test — and for a trust-first product, it’s also your best real way to get customers in year one, because you can explain the neutrality thing in a way a headline can’t, and every happy founding member points you to the next one.

The one-thing-a-day part (this is the real work)

Here’s the piece most people skip, so let me make it stick with a real story.

My friend Andrew Kaplan wrote a book called The Last Law Of Attraction Book You Will Ever Need To Read. The law-of-attraction market is about as crowded as any market gets — you could not pick a more packed shelf. And over roughly five years, he’s sold about 175,000 copies. I asked him on my podcast how he pulled that off, and his answer was simple: “Every single day I do at least one thing in service of the book: write a post, do a podcast, make a YouTube video, post a short on TikTok, give a talk, do a radio show … at least one thing every day, 365 days a year.”

That’s the whole secret. Marketing isn’t a launch you do once and finish. It’s one thing a day, every day. A drumbeat.

So here’s what your one thing a day could look like for this business, pulled from the ways above:

Write one genuinely neutral evidence read on a treatment people search — rapamycin, NMN/NAD, senolytics.
Answer one real question in a longevity forum or newsletter comments (“which of my two age tests should I trust?”).
Send one personal note to someone already spending on tests, offering the founding-member deal.
Reach out to one trusted longevity writer or podcaster about an earned mention.
Post one short, honest “here’s what the study actually showed” clip or thread.
Turn one happy founding member into a testimonial you can point the next person to.
Add one citation or fix to your grading rulebook — the writing that doubles as your product.

Pick one. Do it. Tomorrow, do another. And here’s the honest part you have to sit with before you commit: that daily drumbeat isn’t free — it’s the real, ongoing price of this business. It’s your time, every day, for as long as you run this. Count that cost now, not later.

What a customer really costs you

One term first: CAC just means what you spend, all in, to land one paying customer. The number that matters is CAC against your price. This thing sells for about $99–$149 a year. That’s a low ceiling, and it’s exactly why most paid channels lose money.

Here’s a rough newsletter example (and it’s a rough example — treat it as math, not a promise):

Step	Number	Source / basis
A spot in a 20,000-reader longevity newsletter	~$1,200	$60 CPM, middle of the $40–$100 health CPM range (beehiiv, Newsletrix)
Readers who click	~600 (3%)	3–4% typical newsletter click rate (Newsletrix, Admailr)
Clickers who actually pre-pay a stranger for a “neutral read”	~1–2%	estimate — no direct benchmark; a trust-first buy is hard
Customers you land	~6–12	the math above
Cost to land one customer (CAC)	~$100–$200	estimate

Now read that bottom row against a $129 price. Best case, you roughly break even in year one. Likely case, it costs you more to get a customer than that customer pays you the first year. That’s the whole problem in one table: a paid channel costs about what the customer is worth, so it doesn’t pay for itself here.

Paid social looks cheaper on paper — landing a health-and-wellness customer on Meta runs about $27–$41 (Triple Whale, ScaleWithFuture) — but those numbers are for impulse buys like supplements and cosmetics, where nobody has to believe you before hitting “buy.” A $129 trust-first subscription does way worse than that, so your real cost on that channel would be several times those figures. (And, as you’ll see below, the health-ad rules make it hard to even reach the right people.)

The ways that do make sense are the cheap-or-free ones: reaching out yourself (your time, almost no cash), and evidence writing (your time and patience, almost no cash, but it pays off over years). Pay-per-signup newsletter tools like Sparkloop charge about $1.20–$3.00 per email signup (Admailr) — fine for building a waitlist on the cheap, but remember, a signup still isn’t a sale.

Your first three months

Days 1–14 — the pre-sell. Put up the one-page founding-member offer. Personally reach 30–50 people already spending on longevity tests and ask for real money, not just an email. This is the kill test and your launch list.
Days 15–45 — read the signal, start writing. If people pre-paid, keep going and turn each buyer into a testimonial. Publish your first 3–5 genuinely neutral evidence reads on the treatments people search most (rapamycin, NMN/NAD, senolytics) — the same writing that becomes your grading rulebook.
Days 45–90 — borrow trust once. Have real talks with two or three trusted longevity newsletter writers or podcasters. Aim for an earned mention or a revenue-share deal, not a paid banner — the math above shows a cold paid placement barely breaks even. Keep publishing the whole time. By day 90 you should know two things: did strangers pay for neutrality (from the pre-sell), and is any of your writing starting to get found (from Google)?

Don’t waste money on these

Paid social ads (Meta, Instagram, TikTok). Two reasons. First, the rules: Google and Meta now won’t let you target people by health condition and they restrict “clinically proven”–style claims (Google Ads health-personalization policy; Meta’s Personal Attributes Policy), so you can’t cleanly aim at “people spending on longevity tests” anyway. Second, and bigger: you can’t buy trust with a banner, and trust is the whole product. Your real cost per customer would blow right past the $129 you’d earn.
Broad app-install campaigns. Chasing cheap installs (the going rate is only a few dollars each) gets you the wrong people — installers, not believers — and a trust product dies on a cold install.
Paid influencer promotions. This one’s a landmine for your brand. A paid influencer is the opposite of neutrality — the second money changes hands, the honest-broker promise you’re selling is gone. Same goes for affiliate commissions (sending people to labs or supplements for a cut), which this report already flagged as poison for the brand. Borrowed trust only works when it’s earned, not bought.
Generic “just crank out content” / SEO content mills. Pumping out shallow articles fails twice: it won’t outrank Examine, and thin junk actively wrecks the credibility that’s your only real asset. The writing channel works only if every piece is genuinely rigorous — which is slow and can’t be faked.

So here’s the bottom line on marketing. The only route with a shot is the audience-first one. If you already own a trusted longevity audience, you skip the expensive part (being believed), and the founding-member pre-sell can carry a modest subscription. If you’re starting cold, every channel that scales fast either loses money against a $129 price or breaks the neutrality that’s the whole reason you exist. That’s not a marketing failure — it’s the two-star verdict showing up again, in a new place. And one more thing: this plan is a draft until real customers vote. Once you’re live, come back and rewrite it against what actually happened — plan the marketing, build, market, test, then revisit the plan.

The first version to build

Do NOT try to “connect to all the labs automatically” — TruDiagnostic and its peers offer no way for outside software to plug in, and won’t hand over individual data without consent. Instead, build a web app where a person (1) uploads their TruDiagnostic / Function / Elysium / InsideTracker PDF and connects an Apple Health or Oura export, and (2) gets one clean cross-source view of their biological age with honest warnings about how noisy and non-comparable the tests are, plus (3) a graded-evidence read of each treatment they’ve flagged (rapamycin → the PEARL letdown; NMN/NAD → weak lifespan evidence) with real citations.

Built on PDF-reading, Apple Health exports, and an AI kept strictly on a leash by a hand-written evidence rulebook (that rulebook is the actual treasure). Strict “wellness / information only” wording, every claim cited, no personalized prescribing. Cost: low — one person, AI costs plus hosting, no lab, no hardware; a first version is realistic in about 2 to 4 months. The biggest real costs are (a) writing the grading rulebook and (b) a lawyer’s review of your health wording. You’ll learn the truth about building in weeks to months; you’ll learn the truth about demand (will people pay for an unbundled read?) only by testing — so run a hand-built report or paid pilot with 20 to 50 health-obsessed buyers first.

The cheap test that settles it

Put up a one-page offer: “A neutral, evidence-graded second opinion on your longevity labs — we sell nothing but the honest read, including what the studies say does NOT work. $129/year, founding members.” Send 30 to 50 people who are already spending money on this stuff (from existing longevity forums and newsletters) and require a real pre-payment or a refundable deposit — not just an email address, actual money. Under $500, under two weeks.

Pass mark: roughly 5 to 10%+ of these already-spending buyers pre-pay for a standalone read — even though Superpower gives the reading away at $199 and Function gives it away free with the test. If they won’t put money down on neutrality alone, the idea is dead — and that’s the single question the whole score hangs on.

How sure are we: Very sure on the facts about competitors — Function’s raise, valuation, and AI reader; Superpower’s $199 upload-sync-AI product; PEARL’s null result; the 9-year test wobble are all independently confirmed. Medium-sure on the demand answer: there’s no direct data either way on whether people will pay for a standalone neutral read, but the clear trend of “reading” becoming free is a strong warning sign.

The risks

The big companies close in: Function ($2.5 billion, its own AI reader) and Superpower ($199, already upload-sync-AI) are building this into a bundled offer and own the test-buying relationship — so a standalone reader risks being a feature, not a company.
Getting the data is hard: no clean way to plug into the labs; you depend on people uploading their own files, finicky PDF-reading, and consent forms.
Unproven that people will pay for a standalone read: the labs give reading away to sell the $199-$365 test, and $15-a-month copycat apps already exist.
The rules could shift: the FDA’s January 2026 guidance treats software that “recommends” things to patients as a possible medical device; personalized “advice” triggers device rules and practicing-medicine obligations.
Shaky foundation: the biological-age tests wobble up to 9 years between repeats — build a “we track your trends over time” pitch on shaky signals and you can invent trends that aren’t real.
Neutrality fights against making money: the obvious way to earn (referral commissions) flatly contradicts the honest-broker brand.
The treadmill: the defensible piece has to be re-written constantly as new studies come out — ongoing labor, not a one-time build.

Reasons NOT to do this

The pitch’s core claim — that this “reading” layer is “still open and not consolidated” — is largely false as of 2026: Superpower already sells the product and Function is actively building it with $298 million and a $2.5 billion valuation.
The strongest claimed edge (owning the most long-term data) actually favors the big companies with 200,000+ members and 50 million+ tests; a solo founder starts at zero and stays permanently behind on that.
The genuinely defensible piece (the evidence-grading method) is a modest-earning writing business that never stops needing updates — closer to an Examine.com than a giant, investor-scale company, and Examine already owns “graded evidence.”
The “gather all your data” trick depends on data the founder can’t cleanly get (no plug-in access, consent walls, PDF-reading).
The verdict on your time: easy to build, but low certainty of demand and a closing window — more likely a feature inside a bigger company than a company of its own. So run a hard, cheap demand test before you invest any real founder time.

The strongest case against, from our reviewer (dissent): The main idea is already dead-on-arrival, not just threatened. Superpower sells the pitched product at $199 today, and Function — at a $2.5 billion valuation with $298 million fresh — is building the same thing as a bundled feature while owning the test-buying relationship. Both give the reading away free to sell the $199-$365 test — so the standalone layer is being priced to zero. The solo founder starts at zero on the only large-scale edge, and the fallback asset is a neutrality-branded writing treadmill that earns modestly in a category Examine already owns. A standalone reader is structurally a feature, not a company. The “the window stays open” logic does not apply here — this corner is on fast software timing and is already consolidating around a well-funded company.

Sources

Why is everything here 2 stars or less? Because that’s the honest truth about most business ideas — and every idea we score 0, 1, or 2 stars gets published free, right here. The rare 3-, 4-, and 5-star finds are different: those will go to paid subscribers first, and that tier is opening soon — free subscribers get the first invitation. Join the free list. Or have us investigate your own idea, privately: Request a Dossier ($199).